Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

@article{Barrios2012PhaseIT,
  title={Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.},
  author={Carlos Henrique Barrios and David Hern{\'a}ndez-Barajas and Michael P. Brown and Se-Hoon Lee and Luis Fein and Jin-Hwang Liu and Subramanian Hariharan and Bridget A. Martell and Jinyu Yuan and Akintunde Bello and Zhixiao Wang and Rajiv Mundayat and S Rha},
  journal={Cancer},
  year={2012},
  volume={118 5},
  pages={1252-9}
}
BACKGROUND Sunitinib at 50 mg/day on the 4-weeks-on-2-weeks-off schedule is the current approved regimen for advanced/metastatic renal cell carcinoma (mRCC). Escudier et al reported that continuous, once-daily dosing with sunitinib 37.5 mg had a manageable safety profile and significant antitumor activity as second-line mRCC therapy. In this prospective, multicenter, phase II study, we evaluated the activity of continuous once-daily dosing with sunitinib 37.5 mg as first-line mRCC treatment… CONTINUE READING